Bloomberg Law, August, 26, 2022 A House report detailing coordinated attempts by Trump White House officials to influence the FDA’s pandemic response underscores the need for more transparency at an agency that’s facing historically low public trust, health policy analysts say. The House Select Subcommittee on the Coronavirus Crisis said this week that advisers to former President Donald […]
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA official bolting to Big Tobacco shines a light on the agency’s revolving-door problem
Grid News, August 3, 2022: An FDA official leaving FDA’s Tobacco Science Office to work for Big Tobacco shines a light on the agency’s revolving-door problem. We explain why this undermines FDA’s authority.
Read More »Science says later school start times are healthier. Some High Desert schools aren’t so sure
Daily Press, August 1, 2022: Science says later school start times are healthier. We explain that “If you were designing something to make it very difficult for high school students to learn and concentrate, starting classes at 8 or earlier is what you would design.” But some students disagree.
Read More »Bipartisan bill on antibiotics faces crucial stretch
The Hill, August 1, 2022: A health care bill is facing criticism from some experts who say it could lead to huge spending on new antibiotic drug development that may not improve patient outcomes in the long run. We point out that it could increase antibiotic resistance rather than solve the problem.
Read More »Over-the-counter birth control? Drugmaker seeks FDA approval
Associated Press, July 11, 2022: For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S. Birth control pills are safer than pregnancy, but they are sometimes taken for other reasons.
Read More »